Legal & General Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-94,464
| Closed | -$1.06M | – | 3317 |
|
|
2017
Q3 | $1.06M | Sell |
94,464
-135
| -0.1% | -$1.49K | ﹤0.01% | 1848 |
|
|
2017
Q2 | $1.04M | Buy |
94,599
+11,932
| +14% | +$119K | ﹤0.01% | 1810 |
|
|
2017
Q1 | $809K | Sell |
82,667
-224
| -0.3% | -$2.24K | ﹤0.01% | 1872 |
|
|
2016
Q4 | $895K | Buy |
82,891
+39,577
| +91% | +$396K | ﹤0.01% | 1777 |
|
|
2016
Q3 | $441K | Buy |
43,314
+34,654
| +400% | +$377K | ﹤0.01% | 1750 |
|
|
2016
Q2 | $112K | Hold |
8,660
| – | – | ﹤0.01% | 2031 |
|
|
2016
Q1 | $91K | Sell |
8,660
-442
| -5% | -$3.93K | ﹤0.01% | 2120 |
|
|
2015
Q4 | $83K | Hold |
9,102
| – | – | ﹤0.01% | 2192 |
|
|
2015
Q3 | $63K | Hold |
9,102
| – | – | ﹤0.01% | 2326 |
|
|
2015
Q2 | $86K | Hold |
9,102
| – | – | ﹤0.01% | 2231 |
|
|
2015
Q1 | $80K | Hold |
9,102
| – | – | ﹤0.01% | 2190 |
|
|
2014
Q4 | $80K | Sell |
9,102
-613
| -6% | -$4.96K | ﹤0.01% | 2137 |
|
|
2014
Q3 | $67K | Buy |
+9,715
| New | +$58.2K | ﹤0.01% | 2206 |
|
Legal & General Group's SCLN Position: Q4 2017 in Review
Legal & General Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 94,464 shares — an estimated $1.06M sold.
Legal & General Group first reported a position in SCLN in Q3 2014 and held it in 13 quarters. The position peaked at $1.06M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Legal & General Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Legal & General Group sold 94,464 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $1.06M.
- Legal & General Group first reported a position in Sciclone Pharmaceuticals Inc in Q3 2014 and held it in 13 quarters.
- Legal & General Group's Sciclone Pharmaceuticals Inc position peaked at $1.06M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Legal & General Group's 13F filing for Q4 2017, filed 13 Feb 2018.